Generated first-ever positive quarterly cash flow from operations
Received a record 233 MyoPro® authorizations and orders with 657 additions to the pipeline
Introduces 2025 revenue guidance of $50 million to $53 million
Conference call being held today at 4:30pm Eastern time
BURLINGTON, Mass. (March 10, 2025) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2024. Read more.